Invention Grant
- Patent Title: Antibodies for treatment and diagnosis of inflammatory bowel disease
-
Application No.: US16060766Application Date: 2016-12-09
-
Publication No.: US10647760B2Publication Date: 2020-05-12
- Inventor: Sarah Wulhfard , Alessandra Villa , Catherine Pemberton Ross , Francesca Pretto , Filippa Fleetwood
- Applicant: PHILOGEN S.P.A.
- Applicant Address: IT Siena
- Assignee: PHILOGEN S.P.A.
- Current Assignee: PHILOGEN S.P.A.
- Current Assignee Address: IT Siena
- Agency: Bozicevic, Field & Francis LLP
- Agent Pamela J. Sherwood
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@28ca5d36 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@60b9225e com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@626f2b13
- International Application: PCT/EP2016/080462 WO 20161209
- International Announcement: WO2017/097990 WO 20170615
- Main IPC: C07K16/18
- IPC: C07K16/18 ; C07K16/28 ; A61K47/68 ; A61K39/00 ; C07K16/40

Abstract:
The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.
Public/Granted literature
- US20190062414A1 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE Public/Granted day:2019-02-28
Information query